{"title": "Alzheimer's experts call for changes in FDA drug approval standards", "text": "", "article_link": null, "url": "http://www.eurekalert.org/pub_releases/2017-05/apa-aec051117.php", "region": "", "source_link": null, "funder": "", "meeting": "", "institution": "ResearchersAgainstAlzheimer's", "keywords": ["Biotechnology", " Health Care", " Pharmaceutical Sciences", " Medicine/Health", " Gerontology", " Neurobiology", " Alzheimer's Disease", " Pharmaceutical Science", " Aging", " Memory/Cognitive Processes"], "journal": "", "description": "Leading Alzheimer's disease researchers and a prominent patient advocate today published an analysis, 'Single Endpoint for New Drug Approvals for Alzheimer's Disease,' urging the Food and Drug Administration (FDA) to clarify and modernize its current approach for approving new treatments for Alzheimer's disease.", "date": "Thu, 11 May 2017 04:00:00 GMT"}